#50
Monitored Relevance
Early-stage or contextual signal requiring further evidence before action.
Cannabis Use Disorder
Europe
Mental Health
| Audience | Patients, caregivers, clinicians, and readers tracking cannabis policy and treatment access |
| Primary Topic | Cannabis use disorder treatment availability and quality across Europe |
| Source | More access here |
Cannabis Use Disorder Treatment in Europe, What This 2025 Overview Adds, and What It Still Cannot Tell Us
This is a mixed-methods mapping paper, not a treatment trial, and it offers a useful snapshot of how cannabis-specific services are distributed across Europe, while leaving major questions unanswered about quality, outcomes, and real-world access.
Cannabis use disorder is not a fringe issue in this paper’s framing. The authors describe cannabis as the most frequent reason for first-time drug-related treatment admissions in Europe, and they note that between 8% and 22% of lifetime cannabis users may develop cannabis use disorder. That makes treatment availability a practical public health question, not just an academic one. At the same time, a map of services is not the same thing as proof that people are receiving high-quality, evidence-based care.
This paper gathered information on cannabis-specific treatment programs across 27 EU member states plus the United Kingdom, Norway, and Turkey, for a total of 30 countries. The authors used a mixed-methods approach, combining a survey of National Focal Points connected to the European Drugs Agency, a qualitative review of internal drug and treatment workbooks from 2020 and 2021, and follow-up contact with national experts when details were missing. Programs were only included if they were structured, theory-driven, and specifically tailored to people with cannabis-related problems. Preventive interventions and general harm-reduction strategies were outside the paper’s scope.
The broad finding is that cannabis-specific treatment exists in parts of Europe, but coverage remains patchy. Sixteen of the 30 countries reported cannabis-specific programs. Fifteen countries reported face-to-face cannabis-specific interventions, and nine reported online information, self-help, or therapist-guided programs. The paper also notes that many countries still rely primarily on general substance use treatment programs rather than dedicated cannabis-specific care. Online options appear to have expanded after the COVID period, and the authors describe early emergence of designated cannabis clinics in a few settings, especially for patients with cannabis use disorder plus psychosis or other psychiatric comorbidity.
As evidence, this paper is best understood as a structured policy and service landscape review. It is useful for showing what kinds of programs are reported to exist and where obvious gaps remain. It is not designed to test whether one treatment works better than another, whether access is equitable, or whether patients actually improve. In the evidence hierarchy, that makes it informative for service mapping and planning, but much weaker for clinical decision-making than randomized trials, prospective outcome studies, or high-quality systematic reviews of treatment efficacy.
The biggest limitation is that the paper depends heavily on country-level reporting, internal workbooks, survey responses, and personal communication. That means the picture may be incomplete, uneven, or partly dependent on how national respondents interpreted the questions. The authors explicitly acknowledge that some cannabis-specific approaches may exist at national, regional, or local level without being consistently described in the documents they reviewed. They also acknowledge that for the UK, information came only from personal communication, which may limit validity. Just as importantly, the paper states that most reported programs are not evidence-based, and that little information was available on clinical outcomes or treatment manuals. So the paper can tell us more about reported availability than about actual effectiveness.
This paper does not show that Europe has solved cannabis use disorder treatment. It does not show that cannabis-specific programs are widely accessible, uniformly implemented, or supported by strong outcome data. It also does not show that online treatment expansion has translated into durable clinical benefit. For vulnerable groups, including adolescents, people with severe mental illness, pregnant women, older adults, and others with more complex needs, the paper mainly highlights scarcity rather than resolution. Readers should be careful not to confuse the existence of named programs with proof of broad, effective care.
This paper makes a modest but meaningful contribution. It suggests that cannabis-specific treatment services in Europe have grown over the past decade, especially through regional face-to-face programs and newer online offerings. But the bottom line remains cautious: coverage is still limited, many services are not clearly evidence-based, and the literature on real-world outcomes remains thin. It is a helpful map of a developing treatment landscape, not a confirmation that the landscape is strong enough yet.
| Study Type | Mixed-methods mapping study and narrative overview of treatment availability |
| Population | National treatment systems and reported cannabis-specific programs across 30 European countries |
| Exposure or Intervention | Cannabis-specific psychosocial treatment programs, including face-to-face and online services |
| Comparator | No formal clinical comparator; the paper also contrasts cannabis-specific treatment with general substance use treatment approaches |
| Primary Outcomes | Reported availability, format, coverage, and characteristics of cannabis-specific treatment programs |
| Sample Size or Scope | 30 countries: 27 EU member states plus the United Kingdom, Norway, and Turkey |
| Journal | European Archives of Psychiatry and Clinical Neuroscience |
| Year | 2025 |
| DOI | 10.1007/s00406-025-01964-7 |
| Funding or Conflicts | Funded by the European Drugs Agency, project CT.21.HEA.0103.1. Reported conflicts include consulting roles with EUDA and government bodies, and one author’s prior work on the CANDIS project. |
? Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Frequently Asked Questions
Does this paper show that Europe has strong cannabis use disorder treatment coverage?
No. It shows that cannabis-specific programs exist in parts of Europe, but coverage remains limited and uneven, and many programs are not clearly evidence-based.
Is this a treatment trial?
No. This is a mixed-methods mapping paper that describes reported treatment availability across countries. It does not test whether one treatment works better than another.
What is the most important limitation?
The paper depends heavily on national reporting, internal workbooks, survey responses, and some personal communication. That makes it helpful for landscape mapping, but weaker for judging real-world quality or outcomes.
